FRA:5CV - Deutsche Boerse Ag - NL0015436031 - Common Stock - Currency: EUR
FRA:5CV (4/25/2025, 7:00:00 PM)
2.948
+0.09 (+3.15%)
The current stock price of 5CV.DE is 2.948 EUR. In the past month the price increased by 10.91%. In the past year, price increased by 35.73%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
4AB.DE | ABBVIE INC | 18.36 | 293.65B | ||
1ABBV.MI | ABBVIE INC | 16.92 | 266.76B | ||
AMG.DE | AMGEN INC | 14.26 | 133.79B | ||
GIS.DE | GILEAD SCIENCES INC | 13.47 | 114.50B | ||
1GILD.MI | GILEAD SCIENCES INC | 22.33 | 112.99B | ||
VX1.DE | VERTEX PHARMACEUTICALS INC | 1685.96 | 112.69B | ||
ARGX.BR | ARGENX SE | 355.79 | 33.02B | ||
22UA.DE | BIONTECH SE-ADR | N/A | 22.12B | ||
IDP.DE | BIOGEN INC | 7.16 | 15.20B | ||
0QF.DE | MODERNA INC | N/A | 9.34B | ||
1MRNA.MI | MODERNA INC | N/A | 9.08B | ||
GLPG.AS | GALAPAGOS NV | N/A | 1.56B |
CureVac BV is a clinical-stage biopharmaceutical company, which engages in developing transformative medicines based on messenger ribonucleic acid (mRNA). The company is headquartered in Tuebingen, Baden-Wuerttemberg and currently employs 825 full-time employees. The company went IPO on 2020-08-14. The firm develops transformative medicines based on messenger ribonucleic acid, or mRNA. The firm's mRNAs are designed to prevent infections and to treat diseases by mimicking human biology to synthesize the desired proteins. Its technology platform optimizes mRNA constructs that encode functional proteins which either induce a desired immune response or replace defective or missing proteins using the cell’s intrinsic translation machinery. The firm's product portfolio includes clinical and preclinical candidates across multiple disease indications in prophylactic vaccines, oncology, and molecular therapy. In prophylactic vaccines, the Company is advancing its second-generation mRNA backbone against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and a range of infectious diseases, including seasonal influenza, in collaboration with GSK(Glaxo Smith Kline).
CUREVAC NV
Friedrich-Miescher-Str. 15
Tuebingen BADEN-WUERTTEMBERG DE
Employees: 1086
Company Website: https://www.curevac.com/
Investor Relations: https://www.curevac.com/en/investor-relations/
Phone: 49707198830
The current stock price of 5CV.DE is 2.948 EUR. The price increased by 3.15% in the last trading session.
The exchange symbol of CUREVAC NV is 5CV and it is listed on the Deutsche Boerse Ag exchange.
5CV.DE stock is listed on the Deutsche Boerse Ag exchange.
13 analysts have analysed 5CV.DE and the average price target is 6.1 EUR. This implies a price increase of 106.76% is expected in the next year compared to the current price of 2.948. Check the CUREVAC NV stock analysts ratings, price target forecast and up-and down grades for more detailed information.
CUREVAC NV (5CV.DE) has a market capitalization of 663.77M EUR. This makes 5CV.DE a Small Cap stock.
CUREVAC NV (5CV.DE) currently has 1086 employees.
CUREVAC NV (5CV.DE) has a support level at 2.72 and a resistance level at 2.96. Check the full technical report for a detailed analysis of 5CV.DE support and resistance levels.
The Revenue of CUREVAC NV (5CV.DE) is expected to decline by -87.33% in the next year. Check the estimates tab for more information on the 5CV.DE EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
5CV.DE does not pay a dividend.
CUREVAC NV (5CV.DE) will report earnings on 2025-05-21.
The PE ratio for CUREVAC NV (5CV.DE) is 4.04. This is based on the reported non-GAAP earnings per share of 0.73 and the current share price of 2.948 EUR. Check the full fundamental report for a full analysis of the valuation metrics for 5CV.DE.
ChartMill assigns a technical rating of 4 / 10 to 5CV.DE. When comparing the yearly performance of all stocks, 5CV.DE is one of the better performing stocks in the market, outperforming 81.65% of all stocks.
ChartMill assigns a fundamental rating of 6 / 10 to 5CV.DE. 5CV.DE has an excellent financial health rating, but there are some minor concerns on its profitability.
Over the last trailing twelve months 5CV.DE reported a non-GAAP Earnings per Share(EPS) of 0.73. The EPS increased by 161.86% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | 30.3% | ||
ROA | 20.2% | ||
ROE | 23.28% | ||
Debt/Equity | 0.05 |
ChartMill assigns a Buy % Consensus number of 78% to 5CV.DE. The Buy consensus is the average rating of analysts ratings from 13 analysts.
For the next year, analysts expect an EPS growth of -172.66% and a revenue growth -87.33% for 5CV.DE